<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542425</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-002</org_study_id>
    <nct_id>NCT00542425</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BA058 is effective in building bone in
      postmenopausal women with osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, parallel-group, multi-center, dose-finding study to evaluate the
      effects of BA058 in the treatment of otherwise healthy postmenopausal women with
      osteoporosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Marker of Bone Metabolism, PINP</measure>
    <time_frame>6 months</time_frame>
    <description>PINP, N-terminal propeptide of type I procollagen, is a marker of anabolic bone growth.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bone Mineral Density, Total Spine.</measure>
    <time_frame>6 months</time_frame>
    <description>Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Mineral Density, Femoral Neck.</measure>
    <time_frame>6 months</time_frame>
    <description>Femoral neck bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Mineral Density, Total Hip.</measure>
    <time_frame>6 months</time_frame>
    <description>Total analyzable hip bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Mineral Density, Total Spine.</measure>
    <time_frame>12 months</time_frame>
    <description>Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 48.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 20 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 40 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 80 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>teriparatide 20 µg subcutaneous daily</description>
    <arm_group_label>teriparatide</arm_group_label>
    <other_name>PTH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 20 µg</intervention_name>
    <description>BA058 20 µg subcutaneous daily</description>
    <arm_group_label>BA058 20 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 40 µg</intervention_name>
    <description>BA058 40 µg subcutaneous daily</description>
    <arm_group_label>BA058 40 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 80 µg</intervention_name>
    <description>BA058 80 µg subcutaneous daily</description>
    <arm_group_label>BA058 80 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  The patient has a bone mineral density T-score ≤ 2.5 at the lumbar spine or hip
             (femoral neck) by dual energy x-ray absorptiometry (DXA). Women with a bone mineral
             density T-score of 2.0 or lower and a prior low-trauma forearm, humerus, vertebral,
             sacral, pelvic, hip, femoral, or tibial fracture within the past 5 years, or who have
             an additional risk factor such as age 65 or greater or a strong maternal history of
             osteoporosis defined as a fracture related to osteoporosis or osteoporosis itself as
             determined by BMD criteria, are also study candidates.

          -  The patient is in good general health as determined by medical history and physical
             examination and is without evidence of clinically significant abnormality in the
             opinion of the Investigator.

        Primary Exclusion Criteria:

          -  History of bone disorders (e.g., Paget's disease) other than postmenopausal
             osteoporosis.

          -  Prior treatment with approved or as yet unapproved bone-acting investigational agents.

          -  History of carcinoma, nephrolithiasis or urolithiasis within the past five years or
             osteosarcoma at any time.

          -  History of radiotherapy (radiation therapy).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Radius Health, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radius Health, Inc.</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2007</study_first_posted>
  <results_first_submitted>June 30, 2010</results_first_submitted>
  <results_first_submitted_qc>June 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2010</results_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for the study started in the US, in January 2007. For the initial 24-week treatment period, patients were randomized to study treatment at 30 study centers in the US, Argentina, India and the UK . Eleven of the 30 study centers treated patients in the 24-week treatment extension period in the US, Argentina, and India.</recruitment_details>
      <pre_assignment_details>After eligibility was established, patients entered a 4-week Pretreatment Period during which they received daily Calcium and Vitamin D supplements, were trained in self-injection with the pen devices, and were assessed for additional evaluations at the end of the Pretreatment Period. Patients who remained eligible were randomized on Day 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>BA058 20 µg</title>
        </group>
        <group group_id="P3">
          <title>BA058 40 µg</title>
        </group>
        <group group_id="P4">
          <title>BA058 80 µg</title>
        </group>
        <group group_id="P5">
          <title>Teriparatide</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial 24 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inability to complete procedures</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal of treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended 24 Weeks of Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">Not all patients were eligible for extension study, often due to the regulatory approval timeline.</participants>
                <participants group_id="P2" count="13">Not all patients were eligible for extension study, often due to the regulatory approval timeline.</participants>
                <participants group_id="P3" count="10">Not all patients were eligible for extension study, often due to the regulatory approval timeline.</participants>
                <participants group_id="P4" count="7">Not all patients were eligible for extension study, often due to the regulatory approval timeline.</participants>
                <participants group_id="P5" count="14">Not all patients were eligible for extension study, often due to the regulatory approval timeline.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal of treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>BA058 20 µg</title>
        </group>
        <group group_id="B3">
          <title>BA058 40 µg</title>
        </group>
        <group group_id="B4">
          <title>BA058 80 µg</title>
        </group>
        <group group_id="B5">
          <title>Teriparatide</title>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="45"/>
            <count group_id="B5" value="45"/>
            <count group_id="B6" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="7.11"/>
                    <measurement group_id="B2" value="66.3" spread="6.96"/>
                    <measurement group_id="B3" value="64.5" spread="7.35"/>
                    <measurement group_id="B4" value="64.8" spread="7.21"/>
                    <measurement group_id="B5" value="64.5" spread="7.48"/>
                    <measurement group_id="B6" value="65" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Marker of Bone Metabolism, PINP</title>
        <description>PINP, N-terminal propeptide of type I procollagen, is a marker of anabolic bone growth.</description>
        <time_frame>6 months</time_frame>
        <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 193 of the 221 ITT patients had data available for analysis at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>BA058 20 µg</title>
          </group>
          <group group_id="O3">
            <title>BA058 40 µg</title>
          </group>
          <group group_id="O4">
            <title>BA058 80 µg</title>
          </group>
          <group group_id="O5">
            <title>Teriparatide</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Marker of Bone Metabolism, PINP</title>
          <description>PINP, N-terminal propeptide of type I procollagen, is a marker of anabolic bone growth.</description>
          <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 193 of the 221 ITT patients had data available for analysis at Week 24.</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="42"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="26.47"/>
                    <measurement group_id="O2" value="20.0" spread="61.05"/>
                    <measurement group_id="O3" value="90.8" spread="116.92"/>
                    <measurement group_id="O4" value="97.2" spread="123.88"/>
                    <measurement group_id="O5" value="154.3" spread="213.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Study size provided 95 percent power to detect a difference in means of 114 (ng/mL) for PINP endpoint between BA058 (SD=147.5) and placebo (SD=34.5). Study size was based on Bauer 2006 data and utilized a 2-tailed 2-sample t-test with a significance level of alpha=0.01 with a Bonferonni adjustment for multiple testing. It included a 10 percent adjustment for within study dropouts over 6 months and a 15 percent adjustment to maintain adequate power for a per protocol analysis of key endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Study size provided 95 percent power to detect a difference in means of 114 (ng/mL) for PINP endpoint between BA058 (SD=147.5) and placebo (SD=34.5). Study size was based on Bauer 2006 data and utilized a 2-tailed 2-sample t-test with a significance level of alpha=0.01 with a Bonferonni adjustment for multiple testing. It included a 10 percent adjustment for within study dropouts over 6 months and a 15 percent adjustment to maintain adequate power for a per protocol analysis of key endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Bone Mineral Density, Total Spine.</title>
        <description>Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
        <time_frame>6 months</time_frame>
        <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 187 of the 221 ITT patients had data available for analysis at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>BA058 20 µg</title>
          </group>
          <group group_id="O3">
            <title>BA058 40 µg</title>
          </group>
          <group group_id="O4">
            <title>BA058 80 µg</title>
          </group>
          <group group_id="O5">
            <title>Teriparatide</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density, Total Spine.</title>
          <description>Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
          <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 187 of the 221 ITT patients had data available for analysis at Week 24.</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="3.211"/>
                    <measurement group_id="O2" value="3.30" spread="2.068"/>
                    <measurement group_id="O3" value="5.21" spread="4.427"/>
                    <measurement group_id="O4" value="6.11" spread="3.744"/>
                    <measurement group_id="O5" value="5.47" spread="4.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the BMD endpoint, the planned study size has 80 percent power with alpha=0.02 to detect a difference in mean change from baseline of 3.0 (percent) in BMD for the BA058 group and the BA058 Placebo group using an assumed SD of 3.5-4.0. The estimates for SD are based upon results of lumbar spine BMD presented by Body 2002.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For the BMD endpoint, the planned study size has 80 percent power with alpha=0.02 to detect a difference in mean change from baseline of 3.0 (percent) in BMD for the BA058 group and the BA058 Placebo group using an assumed SD of 3.5-4.0. The estimates for SD are based upon results of lumbar spine BMD presented by Body 2002.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Mineral Density, Femoral Neck.</title>
        <description>Femoral neck bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
        <time_frame>6 months</time_frame>
        <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 182 of the 221 ITT patients had data available for analysis at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>BA058 20 µg</title>
          </group>
          <group group_id="O3">
            <title>BA058 40 µg</title>
          </group>
          <group group_id="O4">
            <title>BA058 80 µg</title>
          </group>
          <group group_id="O5">
            <title>Teriparatide</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density, Femoral Neck.</title>
          <description>Femoral neck bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
          <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 182 of the 221 ITT patients had data available for analysis at Week 24.</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="4.797"/>
                    <measurement group_id="O2" value="2.69" spread="4.022"/>
                    <measurement group_id="O3" value="2.20" spread="4.406"/>
                    <measurement group_id="O4" value="3.07" spread="4.175"/>
                    <measurement group_id="O5" value="1.07" spread="4.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Mineral Density, Total Hip.</title>
        <description>Total analyzable hip bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
        <time_frame>6 months</time_frame>
        <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 182 of the 221 ITT patients had data available for analysis at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>BA058 20 µg</title>
          </group>
          <group group_id="O3">
            <title>BA058 40 µg</title>
          </group>
          <group group_id="O4">
            <title>BA058 80 µg</title>
          </group>
          <group group_id="O5">
            <title>Teriparatide</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density, Total Hip.</title>
          <description>Total analyzable hip bone mineral density (BMD) was analyzed by DXA at Week 24.</description>
          <population>The intent to treat (ITT) population included any patient who received at least one dose of study medication; N=221. 182 of the 221 ITT patients had data available for analysis at Week 24.</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="3.053"/>
                    <measurement group_id="O2" value="1.43" spread="2.639"/>
                    <measurement group_id="O3" value="1.97" spread="3.699"/>
                    <measurement group_id="O4" value="2.60" spread="3.488"/>
                    <measurement group_id="O5" value="0.45" spread="3.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Mineral Density, Total Spine.</title>
        <description>Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 48.</description>
        <time_frame>12 months</time_frame>
        <population>The extension population included any patient who continued in the extended 24 weeks of treatment; N=55. 49 of the 55 extension patients had data available for analysis at Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>BA058 20 µg</title>
          </group>
          <group group_id="O3">
            <title>BA058 40 µg</title>
          </group>
          <group group_id="O4">
            <title>BA058 80 µg</title>
          </group>
          <group group_id="O5">
            <title>Teriparatide</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Mineral Density, Total Spine.</title>
          <description>Total analyzable spine bone mineral density (BMD) was analyzed by DXA at Week 48.</description>
          <population>The extension population included any patient who continued in the extended 24 weeks of treatment; N=55. 49 of the 55 extension patients had data available for analysis at Week 48.</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="3.541"/>
                    <measurement group_id="O2" value="5.14" spread="3.164"/>
                    <measurement group_id="O3" value="9.84" spread="5.313"/>
                    <measurement group_id="O4" value="12.94" spread="3.251"/>
                    <measurement group_id="O5" value="8.63" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For patients treated during the initial 6 months only, AEs were collected for 8 months (1 pre + 6 treatment + 1 post). For patients treated over the extended treatment period of 12 months, AEs were collected for 14 months (1 pre + 12 treatment + 1 post).</time_frame>
      <desc>Method of routinely determining whether or not certain adverse events have occurred was by regular investigator assessment and regular laboratory testing.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>BA058 20 µg</title>
        </group>
        <group group_id="E3">
          <title>BA058 40 µg</title>
        </group>
        <group group_id="E4">
          <title>BA058 80 µg</title>
        </group>
        <group group_id="E5">
          <title>Teriparatide</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral crural hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Injection site hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI/Institution may publish/present results of the Study provided that the Publication is reviewed by the Sponsor for Confidential Information at least 60 days prior to submission. If the Publication contains patent-related information, the submission shall be delayed for 90 days.
The Institution/PI will not publish until after the data from the multi-center study is published in a combined paper as long as it is completed within 18 months from the date of study completion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Director</name_or_title>
      <organization>Radius Health, Inc.</organization>
      <phone>(617) 551-4700</phone>
      <email>info@radiuspharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

